Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis.

摘要

Although long-term suppression of experimental arthritis has been reported for liposomal glucocorticoids, direct effects on subsequent flare-up reactions have not been investigated. The glucocorticoid dexamethasone phosphate (DXM-P) was encapsulated in large, non-PEGylated liposomes (DPPC/DPPG/ Chol, 50/10/40 mol%, size: 295 (SD 15) run) and its therapeutic efficacy was compared with free (non-liposomai) drug in rat antigen-induced arthritis (AIA). The specific aim was to assess the therapeutic persistence of an initial acute phase treatment with liposomal DXM-P on the induction of a subsequent flare-up reaction.